European Medicines Agency seeks stakeholders' views on its reflection paper on patient experience data

Documenti analoghi

• Performance of the accelerated assessment of the European Medicines Agency
  di: Vittorio Del Grosso, et al.
  Pubblicazione: (2025)
• Evidence generation throughout paediatric medicines life cycle: findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation
  di: Dominik Karres, et al.
  Pubblicazione: (2024)
• European Medicines Agency (EMA) commentary on EMA/CHMP Guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low‐sized study populations
  di: Andreas Bonertz, et al.
  Pubblicazione: (2025)
• Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency
  di: Valentina Giunchi, et al.
  Pubblicazione: (2025)
• Analysis of 4616 clinical trial initial submissions received by the Medicines and Healthcare products Regulatory Agency between February 2019 and October 2023
  di: Andrea Manfrin, et al.
  Pubblicazione: (2025)